文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

西维来司他降低心血管手术后急性呼吸窘迫综合征发生率:一项随机临床试验

Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2026-03-02
一句话结论心血管术后ICU患者立即持续静脉西维来司他0.2 mg/kg/h可显著降低ARDS发生率和90天全因死亡率,但作者称初步发现,提示可能为药物治疗选择。

这项单中心、随机、安慰剂对照试验于2024年2月15日至2025年4月16日在中国一家三级学术医疗中心纳入424例连续接受心血管手术的患者,1:1随机接受术后入ICU即开始的持续静脉西维来司他0.2 mg/kg/h(最多7天或至ICU出院)或容积匹配的0.9%氯化钠安慰剂。主要终点ARDS发生率在西维来司他组为16.8%(32/190) vs 安慰剂组31.2%(60/192),P<.001;90天死亡率1.1%(2/190) vs 5.2%(10/192),P=.02。术后中性粒细胞弹性蛋白酶和白细胞介素6等炎症标志物在西维来司他组显著降低。作者认为这些初步发现提示西维来司他可能成为减轻心血管手术后ARDS的药物治疗选择。

要点

  • 心血管术后入ICU即开始持续静脉西维来司他0.2 mg/kg/h(最多7天或至ICU出院),ARDS发生率16.8%(32/190) vs 安慰剂31.2%(60/192),P<.001。
  • 同一方案下90天全因死亡率1.1%(2/190) vs 安慰剂5.2%(10/192),P=.02。
  • 术后第1、3、5、7天中性粒细胞弹性蛋白酶和白细胞介素6等炎症标志物在西维来司他组显著降低。
  • 安全性监测的不良事件两组无差异。
  • 作者结论称这些初步发现提示西维来司他可能成为减轻心血管手术后ARDS的药物治疗选择。

适用人群与场景

  • 连续纳入计划接受心血管手术的患者,包括冠状动脉旁路移植术、瓣膜手术、升主动脉重建、联合手术、先天性心脏缺陷修复和心脏肿瘤切除。
  • 单中心、三级学术医疗中心,中国,2024年2月15日至2025年4月16日纳入,术后随访90天。

处置流程与药物剂量

  • 西维来司他组:术后入ICU即开始持续静脉西维来司他0.2 mg/kg/h,持续最多7天或至ICU出院。
  • 安慰剂组:容积匹配的0.9%氯化钠,按相同时间表给药。

研究设计与关键结果

  • 单中心、随机、安慰剂对照临床试验,424例随机,382例完成试验(平均[SD]年龄62.9[6.2]岁;男性210例[55.0%]),按意向性治疗分析。
  • 主要终点ARDS发生率:西维来司他组16.8%(32/190) vs 安慰剂组31.2%(60/192),P<.001。
  • 90天全因死亡率:西维来司他组1.1%(2/190) vs 安慰剂组5.2%(10/192),P=.02。
  • 术后中性粒细胞弹性蛋白酶和白细胞介素6等炎症标志物在西维来司他组显著降低;安全性监测的不良事件两组无差异。

证据类型、等级与局限

  • 随机、安慰剂对照临床试验。
  • 作者称这些为初步发现,提示西维来司他可能成为药物治疗选择。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些初步发现提示西维来司他可能成为减轻心血管手术后ARDS的药物治疗选择。

指南或共识出处

  • ClinicalTrials.gov Identifier: NCT06276569

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Acute respiratory distress syndrome (ARDS) represents a frequent and serious complication after cardiovascular surgery. Although sivelestat, a specific neutrophil elastase inhibitor, has demonstrated therapeutic potential in preliminary studies, the evidence remains limited by methodological constraints of observational designs and underpowered studies.

OBJECTIVE: To evaluate the efficacy of sivelestat vs placebo in reducing the incidence of postoperative ARDS and associated complications among patients undergoing major cardiovascular procedures.

DESIGN, SETTING, AND PARTICIPANTS: This single-center, randomized, placebo-controlled clinical trial conducted at a tertiary care academic medical center om China enrolled 424 participants between February 15, 2024, and April 16, 2025, with a 90-day postoperative follow-up period. Participants were consecutive patients scheduled for cardiovascular surgery, including coronary artery bypass grafting, valve surgeries, ascending aortic reconstruction, combined procedures, congenital heart defect repairs, and cardiac tumor resections.

INTERVENTIONS: Participants were randomly allocated (1:1) to receive either continuous intravenous sivelestat (0.2 mg/kg/h), initiated immediately on intensive care unit (ICU) admission postoperatively and continued for up to 7 days or until ICU discharge; or volume-matched 0.9% sodium chloride placebo administered on an identical schedule.

MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of ARDS. Secondary outcomes included serial measurements of inflammatory biomarkers, including interleukin 6 and interleukin 8, tumor necrosis factor, systemic immune-inflammation index, and serum neutrophil elastase, on postoperative days 1, 3, 5, and 7, along with ARDS-related clinical outcomes including death, pneumonia, and reintubation. Analysis was performed on an intention-to-treat basis.

RESULTS: Among 424 randomized patients, 382 completed the trial (mean [SD] age, 62.9 [6.2] years; 210 male [55.0%]). Adverse events monitored for safety did not differ between groups. The sivelestat group had significantly lower rates of ARDS (16.8% [32 of 190] vs 31.2% [60 of 192]; P < .001), and 90-day mortality (1.1% [2 of 190] vs 5.2% [10 of 192]; P = .02). Postoperative inflammatory biomarkers, including neutrophil elastase and interleukin 6, were significantly reduced in the sivelestat group.

CONCLUSION AND RELEVANCE: In this single-center, randomized, placebo-controlled clinical trial of patients undergoing cardiovascular surgery, sivelestat significantly reduced ARDS incidence and 90-day all-cause mortality. Sivelestat attenuated neutrophil-driven inflammation by dynamically suppressing neutrophil elastase and reducing key downstream biomarkers. These preliminary findings suggest sivelestat may be a pharmacologic option to mitigate ARDS in cardiovascular procedures.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06276569.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Pan T, Xu C, Wang YP, et al. Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial. JAMA Netw Open. 2026. PMID: 41811317. doi:10.1001/jamanetworkopen.2026.0390

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。